The KDIGO webinar series on Implementing Genetic Testing for CKD in the Real World Setting provides a comprehensive program covering foundational principles, result interpretation, clinical utility, and future directions in renal genetics. Modules 2 – 4 will be CME-accredited.

Module 1 – November 12, 2024

In Module 1 of KDIGO’s four-part webinar series, “Foundational Principles in the Role of Genetics for CKD Management,” Professors Andrew Mallett, MD (Australia), Hila Rasouly, MD (United States), and Ali Gharavi, MD (United States) discuss key messages from KDIGO Guidelines on the prevalence of genetic causes of CKD and foundational principles in the role of genetics for CKD management. This webinar also offers an overview of genetic testing logistics. The webinar took place on November 12, 2024.

Module 2 – December 4, 2024

You can now register for the second module in this series, Hiding in Plain Sight: The Utility of Genetic Testing in Common Forms of CKD.

In this CME webinar, Professors Andrew Mallett, MD (Australia), Emilie Cornec-Le Gall, MD (France), Judy Savige, MD (United States), and Katalin Susztac, MD (United States) will discuss the utility of genetic testing in common forms of CKD. The webinar will also examine the role of genetic testing when diagnosing cystic kidney disease, glomerular disease, and APOL1 kidney disease.

Module 3 – TBA 2025

Module 3 will highlight the value of genetic testing in common CKD forms, with a focus on clinical presentations of cystic, glomerular, and APOL1-related kidney diseases. Experts discuss classic versus atypical presentations, the spectrum of genetic variants across these conditions, and how genetic diagnoses influence prognostic and family planning decisions. Specific attention is given to APOL1’s relevance for African ancestry populations, implications for treatment, and misclassification risks in hypertensive nephrosclerosis or diabetic nephropathy patients.

Module 4 – TBA 2025

Module 4 will offer a forward-looking, conversational session on the evolving field of renal genetics. With an eye to the future, speakers discuss emerging therapies, gaps in variant classification, underrepresentation of diverse ancestry groups, and the rapid pace of discoveries, such as new gene-disease associations and innovative treatments. This module also highlights the potential of polygenic risk scores, pharmacogenomics, and gene-targeted therapies to further transform CKD care in the coming years.